Breast Cancer
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
Exploring how Kazia Therapeutics’ novel nuclear PD-L1 protein degrader, NDL2, works to overcome immunotherapy resistance in advanced solid tumors.
-
KEYNOTE-B49 Shows Pembrolizumab Delays Progression in PD-L1-Positive Breast Cancer
New data from the phase 3 trial indicate that adding immunotherapy to chemotherapy improves progression-free survival in a specific subset of advanced…
-
Flawed Studies Prompt Hormone Therapy Caution for Breast Cancer Survivors
Recent reevaluations of past studies suggest hormone therapy may be safer for breast cancer survivors than previously thought, but doctors remain cautious.
-
UK Trial Aims to Cut Breast Cancer Radiotherapy from Three Weeks to Five Days
Government-funded FAST-Forward Boost trial recruits 1,000 patients across 39 hospitals to test shorter treatment with targeted boost dose.
-
New Study Shows Tucatinib Delays Progression in Breast Cancer Spread to Brain
A Duke-led trial found adding tucatinib to standard care substantially delayed worsening in HER2-positive breast cancer patients with new brain metastases.
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
WASHINGTON, July 7 — A 13-year gap between a mother’s breast cancer diagnosis and her daughter’s own diagnosis has laid bare persistent…
-
FDA Fully Approves Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
INDIANAPOLIS, September 19 — Eli Lilly and Company announced on Sept. 18, 2026, that the U.S. Food and Drug Administration granted full…
-
How Oncotype DX Works: The 21-Gene Recurrence Score Explained
MUNICH, July 17 — A gene expression profiling test that has become a standard tool in breast cancer treatment decisions works by…
-
Clinical Risk Score Helps Guide Chemotherapy Choices for Younger Women After Oncotype DX Test
NEW YORK, July 17 — For patients facing a breast cancer diagnosis, the decision about chemotherapy has long been one of medicine’s…
-
Dr. Joseph Sparano, TAILORx Lead Author, and the Trial That Spared Many Women Chemotherapy
NEW YORK, July 17 — A landmark clinical trial that reshaped how oncologists treat early-stage breast cancer has its roots in the…
-
Oncotype DX Evidence: What TAILORx and NCCN Ratings Show
WASHINGTON, July 17 — The strategic calculus of breast cancer treatment has shifted decisively over the past two decades, driven by a…
-
Oncotype DX Gene Test Spares Many Breast Cancer Patients From Chemotherapy
MADISON, Wisconsin, July 17 — The genomic test Oncotype DX has fundamentally altered the strategic calculus of breast cancer treatment, shifting the…
-
Delphi Diagnostics Offers Endocrine Activity Index Test for Stage II-III Breast Cancer
LONDON, July 17 — The genomic test that changed how oncologists decide whether to give chemotherapy for early breast cancer now has…
-
Pioneering pharmacologist honored for breast cancer breakthrough
WASHINGTON, July 15 — V. Craig Jordan, the British-American pharmacologist whose work turned tamoxifen into a cornerstone of hormone-positive breast cancer therapy,…
-
NYU AI Test Edges Out Oncotype DX in Predicting Breast Cancer Recurrence
NEW YORK, July 12 — A new AI tool from New York University may offer a cheaper alternative to genomic tests for…
-
Oncologist warns breast cancer signs go beyond a lump
LONDON, July 3 — Actress and presenter Lisa Faulkner has revealed she underwent surgery for early-stage breast cancer, a diagnosis she said…
-
Actress Lisa Faulkner reveals early-stage breast cancer after routine mammogram
One woman in the UK receives a breast cancer diagnosis every ten minutes. That statistic, from research charity Breast Cancer Now, is…
-
Anixa Biosciences Gets First Korean Patent for Breast Cancer Vaccine
SAN JOSE, June 29 — Anixa Biosciences has secured its first Korean patent for a breast cancer vaccine, a move that extends…
-
Anixa Biosciences Secures First Korean Patent for Breast Cancer Vaccine
Anixa’s Korean Patent Opens Door to Clinical Trials in Asia SAN JOSE — The patent paperwork is done. Now comes the hard…
-
Columbia and Tübingen Researchers Find Protein NFIL3 Drives CAR T-Cell Exhaustion
Engineered immune cells known as CAR‑T cells have revolutionized treatment for blood cancers, yet their impact on solid tumors such as breast,…
-
FDA Approves Genentech’s Inavolisib for PIK3CA-Mutated Advanced Breast Cancer
On 15 October 2024, the U.S. Food and Drug Administration granted market authorization to Inavolisib, a novel therapy from Genentech, a Roche…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
How Dynasty Trusts Preserve Wealth for a Century Using GST Exemptions
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
How Major Medical Centers Partner With Tech Firms for Next-Gen Proton Therapy
-
FDA Denies Approval for Summit Therapeutics’ Ivonescimab in Lung Cancer
-
How will the next era of precision thoracic oncology change treatment choices for lung‑cancer patients?
-
FDA Approval Moves Astellas’ Padcev Into Curative Bladder Cancer Setting
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
Navigating 7% Mortgage Rates: Strategies for Buying a Home Now
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992






















